IP Library Granted Patent US 9,107,956
Granted Patent B2
US 9,107,956 · App. 14/055,581 · Granted Aug 18, 2015

Oligomer-protease inhibitor conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,107,956
App. No.
14/055,581
Granted
Aug 18, 2015
Kind
B2
Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.

Claims (19)

1. A compound of the following Formula

wherein:

X is a stable amide linkage;

POLY is a poly(alkylene oxide) of between 1 and 30 monomers;

and R 1 is benzyloxycarbonyl or 2-quinolylcarbonyl.

2. The compound of claim 1 , wherein R 1 is benzyloxycarbonyl.

3. The compound of claim 1 , wherein R 1 is 2-quinolylcarbonyl.

4. The compound of claim 1 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).

5. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is made of between 1 and 10 monomers.

6. The compound of claim 4 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

7. The compound of claim 1 , wherein R 1 is benzyloxycarbonyl, the water-soluble, non-peptidic oligomer is a poly(ethylene oxide) made of between 1 and 10 monomers and includes a methoxy end-capping moiety, and the stable linkage is an amide.

8. The compound of claim 1 , wherein R 1 is 2-quinolylcarbonyl, the water-soluble, non-peptidic oligomer is a poly(ethylene oxide) made of between 1 and 10 monomers and includes a methoxy end-capping moiety, and the stable linkage is an amide.

9. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.

10. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.

11. A method of inhibiting protease activity in a subject in need thereof, the method comprising administering a compound of claim 1 .

12. A compound of the following formula:

wherein n is 3.

13. A compound of the following formula:

wherein n is 5.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 31838, FRAME 0343 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036876/0138 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY AGREEMENT Recorded Dec 18, 2013
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 031838/0343 →